Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns

Orexigen brought a robust risk management plan and a post-market surveillance program to the Dec. 7 advisory committee review of its weight-loss drug Contrave, forestalling some of the questions that arose during assessments of other compounds seeking to enter the obesity space.